1 completed, 1 recruiting, 1 terminated. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Recruiting 1, Terminated 1 |
Follow Bladder Neoplasm: new trials by email Literature Review of Bladder Neoplasm trials Research Report on Bladder Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Imaging Study of [89Zr]DFO-YS5 for Cancer Detection [89Zr]DFO-YS5, Positron Emission Tomography (PET)-Computerized tomography (CT) - Bladder Cancer, Nerve Sheath Tumor | Phase 1 | Recruiting | Robert Flavell, MD, PhD | 40 | 2026-06-15 | 2026-10-01 |
| A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma IK-175, IK-175 and nivolumab - Urothelial Carcinoma, Urothelial Carcinoma Bladder | Phase 1 | Completed | Ikena Oncology | 78 | 2019-12-18 | 2024-03-15 |
| A Study of MLN8054 in Patients With Advanced Solid Tumors MLN8054 - Breast Neoplasm, Colon Neoplasm | Phase 1 | Terminated | Millennium Pharmaceuticals, Inc. | 63 | 2005-10-01 | 2008-04-01 |
Urinary Bladder Neoplasms (3) · Breast Neoplasms (1) · Carcinoma, Transitional Cell (1) · Colonic Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Nerve Sheath Neoplasms (1) · Pancreatic Neoplasms (1) · Pyloric Stenosis, Hypertrophic (1) · Urinary Bladder Diseases (1)
Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Male Urogenital Diseases (3) · Neoplasms by Site (3) · Urogenital Diseases (3) · Urogenital Neoplasms (3) · Urologic Diseases (3) · Urologic Neoplasms (3) · Digestive System Diseases (2) · Gastrointestinal Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Urinary Bladder Diseases (2) · Breast Diseases (1) · Carcinoma (1)
MLN8054 (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1)
Ikena Oncology (1) · Millennium Pharmaceuticals, Inc. (1) · Robert Flavell, MD, PhD (1)
United States (3)
Karim Malek, MD (1) · Robert Flavell, MD (1)